Cytos Biotechnology AG
18
0
0
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
11.1%
2 terminated/withdrawn out of 18 trials
88.9%
+2.4% vs industry average
0%
0 trials in Phase 3/4
6%
1 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (18)
CYT003-QbG10, a TLR9-agonist, for Treatment of Uncontrolled Moderate to Severe Allergic Asthma
Role: lead
CYT003 in Patients With Mild to Moderate Allergic Asthma Not Sufficiently Controlled on Inhaled Glucocorticosteroids
Role: lead
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Role: lead
Safety, Tolerability, Pharmacodynamic Effects and Preliminary Evidence for Efficacy of the Anti-Hypertension Vaccine CYT006-AngQb
Role: lead
Safety, Tolerability and Pharmacodynamics of CYT013-IL1bQb in Patients With Type 2 Diabetes
Role: lead
CYT003-QbG10 for Treatment of Allergic Asthma Bronchial
Role: lead
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Role: lead
Efficacy and Safety of Nicotine-Qbeta Vaccine in Smokers
Role: lead
Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy
Role: lead
Safety, Tolerability and Efficacy of a Vaccine Against Essential Hypertension
Role: lead
Study to Evaluate Safety and Tolerability, Pharmacodynamic Effects and Exploratory Efficacy of a Vaccine Against Essential Hypertension
Role: lead
A Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Role: lead
Study to Investigate an Immunomodulatory Therapy in Adult Patients With Perennial Allergic Rhinoconjunctivitis
Role: lead
Effect of an Allergen Vaccine in Patients With Allergic Rhino-Conjunctivitis and Asthma Due to House Dust Mite Allergy
Role: lead
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
Role: lead
Safety and Efficacy of an Allergen Vaccine in Grass-Pollen Allergy
Role: lead
Safety and Immunogenicity of a Melan-A VLP Vaccine in Early Stage Melanoma Patients
Role: lead
Safety and Immunogenicity of a Melan-A VLP Vaccine in Advanced Stage Melanoma Patients
Role: lead
All 18 trials loaded